Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COPPER(II) COMPLEX C3 is a binuclear copper(II) complex being investigated as a potential alternative to platinum-based chemotherapy. It demonstrates an affinity for binding to the minor groove of B-form DNA, which is hypothesized to induce a local transition from B-form to Z-form DNA. In vitro studies have shown that it exhibits moderate but selective cytotoxic effects against colon cancer cells, arresting them in the G2/M phase of the cell cycle. Furthermore, in a murine colon cancer model, this complex significantly reduced the expression of inflammatory molecules such as pro-IL-1β, TNF-α, ICAM-1, and VCAM-1, leading to reduced tumor growth and metastasis in the lung and liver.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on COPPER(II) COMPLEX C3.